ImmuPharma (LON:IMM) Shares Down 14.6% – Should You Sell?

ImmuPharma plc (LON:IMMGet Free Report)’s stock price dropped 14.6% during mid-day trading on Tuesday . The company traded as low as GBX 3.20 ($0.04) and last traded at GBX 3.20 ($0.04). Approximately 13,200,714 shares changed hands during mid-day trading, a decline of 53% from the average daily volume of 28,314,303 shares. The stock had previously closed at GBX 3.75 ($0.05).

ImmuPharma Price Performance

The stock has a market capitalization of £13.33 million, a P/E ratio of -320.00 and a beta of 1.53. The stock’s fifty day moving average is GBX 1.48 and its 200-day moving average is GBX 1.66.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzorâ„¢), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Recommended Stories

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.